Small Cell Lung Cancer: Screening of Kinase Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Small cell lung cancer (SCLC) is characterized by numerous circulating tumor cells (CTCs) contributing to metastasis and drug resistance.
• Kinases, activated by growth factors, are crucial for SCLC proliferation, making them potential therapeutic targets.
• Despite targeting kinases like IGF-1R and VEGFR, clinical trials with tyrosine kinase inhibitors (TKIs) in SCLC have yielded disappointing results.

Purpose of the Study:

• To investigate the efficacy of kinase inhibitors against SCLC circulating tumor cells (CTCs).
• To evaluate whether testing kinase inhibitors against SCLC tumorospheres predicts clinical activity better than testing against single CTCs.

Main Methods:

• Screening of a kinase inhibitor library against single SCLC CTCs and SCLC tumorospheres (BHGc10 spheroids).
• Assessing the activity of various kinase inhibitors, including those previously tested in clinical trials.

Main Results:

• Most kinase inhibitors showed activity against single SCLC CTCs.
• SCLC tumorospheres exhibited high chemoresistance to most tested kinase inhibitors.
• Only a few hydrophobic multitarget inhibitors were effective against tumorospheres.
• Drugs that failed in clinical trials targeting IGF-1R, AURORA kinase, and Polo kinases showed low activity against CTC tumorospheres.

Conclusions:

• Preclinical efficacy of kinase inhibitors against single SCLC cells does not accurately predict clinical outcomes.
• Testing kinase inhibitors against SCLC tumorospheres is a more reliable method for predicting potential clinical activity.
• This approach may improve the selection of effective kinase inhibitors for SCLC treatment.